1. Baadhista iyo daawaynta koowaad ee kansarka sanbabada
Bukaan-socodka Lu waxaa laga helay adenocarcinoma sambabada iyo qanjidhada qanjidhada qanjidhada Agoosto 26, 2005. Lobectomy hoose ee bidix ayaa la sameeyay Sebtembar 22, 2005. Carboplatin oo lagu daray taxotere ayaa la isticmaalay 4 jeer qaliinka ka dib. Agoosto 3, 2007, sababtoo ah dhiigbaxa pleural, cudurka waxaa la xaqiijiyay inuu soo noqnoqonayo, waxaana lagu daaweeyay Tarceva (tirada wareegyada lama garanayo). Janaayo 8, 2008, horumarka kansarka ayaa laga helay dib u eegista, ka dibna daawaynta Tarceva waa la joojiyay waxaana daawaynta Libita la bilaabay 16 wareeg. Isla mar ahaantaana, metastasis sinta vertebral ayaa la helay waxaana la sameeyay 4 wareeg oo Zetai ah.
2. Marka ugu horeysa ee laga qaybqaato tijaabooyinka kiliinikada, xaaladdu waa la xakameynayaa.
In July 2010, Mr. Lu reexamined a large area of brain metastasis and found dozens of small lesions in the brain. He also tested positive for the EML4-ALK fusion gene at the University of Chicago School of Medicine. The whole brain radiation therapy was then used to control the lesions, and the second phase of crizotinib drug trial was started at St. Louis University Hospital. During the treatment, the condition was stably controlled, but a re-examination in May 2012 found that the cancer had progressed slightly, and the buro was suspected to be resistant to crizotinib. He stopped crizotinib on July 18, 2012.
3. Tijaabadii labaad ee bukaan-socodka, burada ayaa si cad u baaba'day.
On August 6, 2012, Mr. Lu participated in the AP26113 drug tijaabada caafimaadka at Denver Hospital. In October, the PET examination showed that the tumor disappeared and the buro maskaxda ku taal decreased and became large.
4. Soo ogow isbeddellada hidde-sideyaasha ee naadir ah oo aad u rajaynayso ka qaybqaadashada tijaabooyin cusub oo caafimaad
Dib-u-eegistii bishii Luulyo 2014, PET-da oo dhan waxay muujisay: Nabarada maskaxdu waxay ahaayeen kuwo deggan asal ahaan, xabadkuna waxay lahaayeen horumar muuqda. Maajo 12, 2014, laga shakiyay anti-AP26113 lymfa (3 unug, ugu weyn 1.1 cm) khadadka unugyada dhaqanka ayaa lagu sameeyay Isbitaalka Guud ee Massachusetts waxayna sii wateen qaadashada AP26113.
In August 2014, the doctor called and found that Mr. Lu’s new tumor tissue sequencing detected rare or unseen mutations. This mutation was only reported in ALK-positive children’s neuroblastoma and inflammatory myofibroblastoma. Previous research reports and medical evidence have shown that crizotinib cannot cope with the resistant neuroblastoma caused by this mutation. New genetic test results indicate that Mr. Lu may need to find new drugs for treatment.
On December 8, 2014, after a doctor’s analysis and decision, Mr. Lu was approved to increase the dosage of AP26113 and changed it to 240 mg per day, so the drug replacement plan was temporarily delayed. After observing the efficacy, he decided whether to change the drug and participate in other clinical trials. The patient learned through the hospital that NIVOLUMAB monoclonal antibody immunotherapy phase 3/4 drug test is recruiting lung cancer patients on a large scale, and Mr. Lu is fully confident of the future anti-cancer.
